Adaptive (ADPT) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$308.1M

Revenue (quarter)

$71.6M

Revenue growth (year over year)

+21.53%

Gross profit (trailing twelve months)

$232.8M

Gross margin

75.57%

Net income (trailing twelve months)

−$64.0M

Net income (quarter)

−$39.9M

Net income growth (year over year)

−56.06%

Net margin

−20.77%

Return on equity

−39.58%

EPS (trailing twelve months)

−$0.40

Book value per share

$0.90

P/E (trailing twelve months)

—

Price to book

27.14

Debt to assets

76.48%

Payout ratio

—

Dividend yield

—

Company profile

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

• Is Adaptive (ADPT) profitable?

  No. Adaptive reported a net loss of $64.0M over the trailing twelve months.

• How much revenue does Adaptive (ADPT) make?

  Adaptive generated $308.1M in revenue over the trailing twelve months, up 21.53% year over year.

• How do I buy stock in Adaptive (ADPT)?

  ADPT trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.